Journals / Meme Sağlığı Dergisi / 2012 / Cilt: 8 - Sayı: 4

Predictive molecular and gemetic factors influencing local control in breast cancer

Meme kanserimde yerel kontrole etki eden prediktif moleküler ve genetik faktörler

Pages
169–174
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, molecular and genetic predictive factors that could be effective in the local control of breast cancer have been focused on, and a review of studies data conducted on the predictive value of the factors such as molecular classification, multigene tests, radiation resistance, DNA repair capacity, signaling pathways, cancer stem cells, and inhibition of CYP2D6 on local control was presented.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Breast cancer is a heterogeneous group of different histological subtypes, which are based on various molecular and genetic factors.
📊
Key Findings & Data:Today, genetic and biotechnological advances caused significant progresses in molecular oncology, which is reflected in clinical oncology.
💡
Conclusion & Impact:In this article, molecular and genetic predictive factors that could be effective in the local control of breast cancer have been focused on, and a review of studies data conducted on the predictive value of the factors such as molecular classification, multigene tests, radiation resistance, DNA repair capacity, signaling pathways, cancer stem cells, and inhibition of CYP2D6 on local control was presented.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Breast cancer is a heterogeneous group of different histological subtypes, which are based on various molecular and genetic factors. All patients are given radiotherapy after breast-conserving surgery, which is actually considered unnecessary in two-thirds of these patients. Therefore, the fact that which patients should be administered radiotherapy has gained great importance. In this respect, known clinical and histopathological prognostic factors can not be sufficient to predict local control. Today, genetic and biotechnological advances caused significant progresses in molecular oncology, which is reflected in clinical oncology. In this article, molecular and genetic predictive factors that could be effective in the local control of breast cancer have been focused on, and a review of studies data conducted on the predictive value of the factors such as molecular classification, multigene tests, radiation resistance, DNA repair capacity, signaling pathways, cancer stem cells, and inhibition of CYP2D6 on local control was presented.

Özet

Meme kanseri farklı histolojik alt tiplerden oluşan heterojen bir grup olup bu değişkenliklerin altında molekuler ve genetik faktörler yatmaktadır. Meme koruyucu cerrahi sonrası her hastaya radyoterapi verilirken aslında hastaların üçte ikisi boşuna radyoterapi almaktadır. Bu nedenle hangi hastaların tedavi alması gerektiği çok önem kazanmaktadır. Bilinen klinik ve histopatolojik prognostik faktörler bu konuda yerel kontrolü tahmin etmede yardımcı olmaya yetmemektedir. Günümüzde genetik ve biyoteknolojik gelişmeler moleküler onkolojide büyük aşamalara neden olmuş, bu durum klinik onkolojiye yansımıştır. Bu yazıda meme kanserinde yerel kontrole etkili olabilecek molekuler ve genetik prediktif faktörler üzerinde durulmuş, moleküler sınıflama, multigen testler, radyoterapi direnci, DNA tamir kapasitesi, sinyal yolakları, kanser kök hücreleri, CYP2D6 inhibisyonu gibi etkenlerin yerel kontrol üzerindeki prediktif değeri için yapılan çalışma sonuçlarından bir derleme hazırlanmıştır.

🔖

Cite This Article

HAYDAROĞLU, A. (2012). Predictive molecular and gemetic factors influencing local control in breast cancer. Meme Sağlığı Dergisi, Cilt: 8 - Sayı: 4, 169–174. https://ajindex.com/articles/278065

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011; 378: 771–784. (PMID:22019144) 2. van der Leij F, Elkhuizen PH, Bartelink H, van de Vijver MJ. Predictive Factors for Local Recurrence in Breast Cancer. Semin Radiat Oncol 2012; 22: 100-107. (PMID: 22385917
  2. Haydaroglu A. Meme Kanseri Kök Hücresi. In:Haydaroglu A. Ed. Meme kanserine molekuler ve genetik yaklaşım. I. Baskı. Ege Üniversitesi Yayınları, ISBN: 978-975-483-928-9, Bornova, İzmir. 2011
  3. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members. Strategies for subtypes-dealing with the diversity of breastcancer: Highlights of the St Gallen International Expert Consensus on thePrimary Therapy of Early Breast Cancer 2011. Annals of Oncology 2011; 22: 1736–1747. (PMID:21709140
  4. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008;14(5): 1368-1376. (PMID:18316557
  5. Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest 2008;26:1-10. (PMID:18181038
  6. Perou MC. Molecular Stratification of Triple-Negative Breast Cancers. The Oncologist 2010; 15: 39–48. (PMID:21278442
  7. Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and Her-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008 26: 2373-2378. (PMID:18413639
  8. Kyndi M, Sorensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J; Danish Breast Cancer Cooperative Group. Estrogen receptor, progesterone receptor, Her-2, and response to postmastectomy radiotherapy in high-risk breast cancer: The Danish Breast Cancer Cooperative Group. J Clin Oncol 2008. 26: 1419-1426. (PMID:18285604
  9. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V,